Deals In Depth: May 2016
Executive Summary
Biogen signed a $2bn deal with UPenn focused on gene therapy; Thermo Fisher made its second major acquisition this year, paying over $4bn for FEI. Early-stage venture funding and FOPOs made up more than half of the month's total $1.6bn in biopharma financing, and big debt offerings from Wright Medical and Teleflex dominated device financing.